202 related articles for article (PubMed ID: 20171921)
1. Safety of rituximab in rheumatoid arthritis patients with a history of severe or recurrent bacterial infection: observational study of 30 cases in everyday practice.
Toussirot E; Pertuiset E; Sordet C; Augé B; Wendling D; Pallot-Pradès B; Collet P; Lohse A; Balblanc JC
Joint Bone Spine; 2010 Mar; 77(2):142-5. PubMed ID: 20171921
[TBL] [Abstract][Full Text] [Related]
2. Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry.
Gottenberg JE; Ravaud P; Bardin T; Cacoub P; Cantagrel A; Combe B; Dougados M; Flipo RM; Godeau B; Guillevin L; Le Loët X; Hachulla E; Schaeverbeke T; Sibilia J; Baron G; Mariette X;
Arthritis Rheum; 2010 Sep; 62(9):2625-32. PubMed ID: 20506353
[TBL] [Abstract][Full Text] [Related]
3. Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor alpha antagonists.
Curtis JR; Patkar N; Xie A; Martin C; Allison JJ; Saag M; Shatin D; Saag KG
Arthritis Rheum; 2007 Apr; 56(4):1125-33. PubMed ID: 17393394
[TBL] [Abstract][Full Text] [Related]
4. Safety of rituximab in rheumatoid arthritis: a long-term prospective single-center study of gammaglobulin concentrations and infections.
Isvy A; Meunier M; Gobeaux-Chenevier C; Maury E; Wipff J; Job-Deslandre C; Kahan A; Allanore Y
Joint Bone Spine; 2012 Jul; 79(4):365-9. PubMed ID: 22285615
[TBL] [Abstract][Full Text] [Related]
5. Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials.
Salliot C; Dougados M; Gossec L
Ann Rheum Dis; 2009 Jan; 68(1):25-32. PubMed ID: 18203761
[TBL] [Abstract][Full Text] [Related]
6. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register.
Dixon WG; Watson K; Lunt M; Hyrich KL; Silman AJ; Symmons DP;
Arthritis Rheum; 2006 Aug; 54(8):2368-76. PubMed ID: 16868999
[TBL] [Abstract][Full Text] [Related]
7. Safety of biological therapies following rituximab treatment in rheumatoid arthritis patients.
Genovese MC; Breedveld FC; Emery P; Cohen S; Keystone E; Matteson EL; Baptiste Y; Chai A; Burke L; Reiss W; Sweetser M; Shaw TM
Ann Rheum Dis; 2009 Dec; 68(12):1894-7. PubMed ID: 19155233
[TBL] [Abstract][Full Text] [Related]
8. Repeated B lymphocyte depletion with rituximab in rheumatoid arthritis over 7 yrs.
Popa C; Leandro MJ; Cambridge G; Edwards JC
Rheumatology (Oxford); 2007 Apr; 46(4):626-30. PubMed ID: 17189244
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of the safety of rituximab in combination with a tumor necrosis factor inhibitor and methotrexate in patients with active rheumatoid arthritis: results from a randomized controlled trial.
Greenwald MW; Shergy WJ; Kaine JL; Sweetser MT; Gilder K; Linnik MD
Arthritis Rheum; 2011 Mar; 63(3):622-32. PubMed ID: 21360491
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of rituximab in patients with rheumatoid arthritis refractory to disease modifying antirheumatic drugs and anti-tumor necrosis factor-alpha treatment.
Higashida J; Wun T; Schmidt S; Naguwa SM; Tuscano JM
J Rheumatol; 2005 Nov; 32(11):2109-15. PubMed ID: 16265687
[TBL] [Abstract][Full Text] [Related]
11. A retrospective chart review of the use of rituximab for the treatment of rheumatoid arthritis in Australian rheumatology practice.
Nicholls D; Zochling J; Boers A; Champion G; Mathers D; Riordan J; Youssef P; Scott J; Griffiths H
Int J Rheum Dis; 2014 Sep; 17(7):755-61. PubMed ID: 24131467
[TBL] [Abstract][Full Text] [Related]
12. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis).
Furst DE; Schiff MH; Fleischmann RM; Strand V; Birbara CA; Compagnone D; Fischkoff SA; Chartash EK
J Rheumatol; 2003 Dec; 30(12):2563-71. PubMed ID: 14719195
[TBL] [Abstract][Full Text] [Related]
13. The infectious profiles of anti-tumor necrosis factor agents in a Thai population: a retrospective study a the university-based hospital.
Suwannalai P; Auethavekiat P; Udomsubpayakul U; Janvitayanujit S
Int J Rheum Dis; 2009 Jul; 12(2):118-24. PubMed ID: 20374328
[TBL] [Abstract][Full Text] [Related]
14. Risk of hospitalized bacterial infections associated with biologic treatment among US veterans with rheumatoid arthritis.
Curtis JR; Yang S; Patkar NM; Chen L; Singh JA; Cannon GW; Mikuls TR; Delzell E; Saag KG; Safford MM; DuVall S; Alexander K; Napalkov P; Winthrop KL; Burton MJ; Kamauu A; Baddley JW
Arthritis Care Res (Hoboken); 2014 Jul; 66(7):990-7. PubMed ID: 24470378
[TBL] [Abstract][Full Text] [Related]
15. Risk of infections in rheumatoid arthritis patients switching from anti-TNF agents to rituximab, abatacept, or another anti-TNF agent, a retrospective administrative claims analysis.
Johnston SS; Turpcu A; Shi N; Fowler R; Chu BC; Alexander K
Semin Arthritis Rheum; 2013 Aug; 43(1):39-47. PubMed ID: 23453683
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of rituximab in the treatment of rheumatoid arthritis. Influence of serologic status, coprescription of methotrexate and prior TNF-alpha inhibitors exposure.
Solau-Gervais E; Prudhomme C; Philippe P; Duhamel A; Dupont-Créteur C; Legrand JL; Houvenagel E; Flipo RM
Joint Bone Spine; 2012 May; 79(3):281-4. PubMed ID: 21724444
[TBL] [Abstract][Full Text] [Related]
17. Serious bacterial infections in patients with rheumatoid arthritis under anti-TNF-alpha therapy.
Kroesen S; Widmer AF; Tyndall A; Hasler P
Rheumatology (Oxford); 2003 May; 42(5):617-21. PubMed ID: 12709536
[TBL] [Abstract][Full Text] [Related]
18. Anti-tumor necrosis factor alpha therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis.
Schneeweiss S; Setoguchi S; Weinblatt ME; Katz JN; Avorn J; Sax PE; Levin R; Solomon DH
Arthritis Rheum; 2007 Jun; 56(6):1754-64. PubMed ID: 17530704
[TBL] [Abstract][Full Text] [Related]
19. Rituximab in rheumatoid arthritis and the risk of malignancies: report from a French cohort.
Slimani S; Lukas C; Combe B; Morel J
Joint Bone Spine; 2011 Oct; 78(5):484-7. PubMed ID: 21196130
[TBL] [Abstract][Full Text] [Related]
20. Serious infections in patients with rheumatoid arthritis and other immune-mediated connective tissue diseases exposed to anti-TNF or rituximab: data from the Spanish registry BIOBADASER 2.0.
Cobo-Ibáñez T; Descalzo MÁ; Loza-Santamaría E; Carmona L; Muñoz-Fernández S
Rheumatol Int; 2014 Jul; 34(7):953-61. PubMed ID: 24414744
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
